Product Description: Falnidamol (BIBX 1382) is an orally active, selective EGFR tyrosine kinase inhibitor with an IC50 of 3 nM. Falnidamol displays > 1000-fold lower potency against ErbB2 (IC50=3.4 μM) and a range of other related tyrosine kinases (IC50>10 μM). Falnidamol is a pyrimido-pyrimidine compound and has anti-cancer activity[1][2].
Applications: Cancer-Kinase/protease
Formula: C18H19ClFN7
References: [1]Solca FF, et al. Inhibition of epidermal growth factor receptor activity by two pyrimidopyrimidine derivatives. J Pharmacol Exp Ther. 2004 Nov;311(2):502-9./[2]Dittrich Ch, et al. Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80.
CAS Number: 196612-93-8
Molecular Weight: 387.84
Compound Purity: 99.41
Research Area: Cancer
Solubility: DMSO : 31.25 mg/mL (ultrasonic;warming;heat to 60°C)
Target: EGFR
Deutsch
English
